Altmetrics
Downloads
119
Views
65
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
10 October 2023
Posted:
11 October 2023
You are already at the latest version
AOP Severity at 21 days of life | |||||||||
---|---|---|---|---|---|---|---|---|---|
AOP at 21 days of life | Mild | Moderate | Severe | ||||||
Subgrouping | Total Populati-on (n) | No. of Events | Percent with Events | No. of Events | Percent with Events | No. of Events | Percent with Events | No. of Events | Percent with Events |
Total | 108 | 78 | 72.22% | 17 | 15.74% | 60 | 55.56% | 1 | 0.93% |
Sex | |||||||||
Male | 64 | 50 | 78.13% | 7 | 10.94% | 43 | 67.19% | 0 | 0.00% |
Female | 44 | 28 | 63.64% | 10 | 22.73% | 17 | 38.64% | 1 | 2.27% |
Gestational age (wks) | |||||||||
32–37 | 35 | 20 | 57.14% | 7 | 20.00% | 13 | 37.14% | 0 | 0.00% |
28–31 | 55 | 42 | 76.36% | 9 | 16.36% | 32 | 58.18% | 1 | 1.82% |
<28 | 18 | 16 | 88.89% | 1 | 5.56% | 15 | 83.33% | 0 | 0.00% |
Body Weight (g) | |||||||||
1500–2499 | 40 | 25 | 62.50% | 9 | 22.50% | 16 | 40.00% | 0 | 0.00% |
1000–1499 | 47 | 35 | 74.47% | 6 | 12.77% | 29 | 61.70% | 0 | 0.00% |
<1000 | 21 | 18 | 85.71% | 2 | 9.52% | 15 | 71.43% | 1 | 4.76% |
Apgar 1 min | |||||||||
7–10 | 52 | 34 | 65.38% | 6 | 11.54% | 28 | 53.85% | 0 | 0.00% |
4–6 | 34 | 26 | 76.47% | 8 | 23.53% | 17 | 50.00% | 1 | 2.94% |
0–3 | 22 | 18 | 81.82% | 3 | 13.64% | 15 | 68.18% | 0 | 0.00% |
Apgar 5 min | |||||||||
7–10 | 62 | 43 | 69.35% | 10 | 16.13% | 33 | 53.23% | 0 | 0.00% |
4–6 | 45 | 34 | 75.56% | 7 | 15.56% | 26 | 57.78% | 1 | 2.22% |
0–3 | 1 | 1 | 100.00% | 0 | 0.00% | 1 | 100.00% | 0 | 0.00% |
Normal LDH at 1 day of life (135–750 U/L) | |||||||||
Yes | 60 | 42 | 70.00% | 12 | 20.00% | 30 | 50.00% | 0 | 0.00% |
No | 48 | 36 | 75.00% | 5 | 10.42% | 30 | 62.50% | 1 | 2.08% |
Normal aPTT at 1 day of life (23–35 s) | |||||||||
Yes | 13 | 12 | 92.31% | 0 | 0.00% | 12 | 92.31% | 0 | 0.00% |
No | 95 | 66 | 69.47% | 17 | 17.89% | 48 | 50.53% | 1 | 1.05% |
Normal Prothrombin Time 1 day of life (11–14 s) | |||||||||
Yes | 42 | 28 | 66.67% | 7 | 16.67% | 21 | 50.00% | 0 | 0.00% |
No | 66 | 50 | 75.76% | 10 | 15.15% | 39 | 59.09% | 1 | 1.52% |
Iron administered within 7–21 days of life | |||||||||
Yes | 60 | 4 | 57.14% | 1 | 14.29% | 3 | 42.86% | 0 | 0.00% |
No | 48 | 74 | 73.27% | 16 | 15.84% | 57 | 56.44% | 1 | 0.99% |
AOP at 1 day of life | |||||||||
Yes | 7 | 31 | 63.27% | 10 | 20.41% | 21 | 42.86% | 0 | 0.00% |
No | 101 | 47 | 79.66% | 7 | 11.86% | 39 | 66.10% | 1 | 1.69% |
Transfusions within 21 days of life | |||
---|---|---|---|
Subgrouping | Total Population (n) | No. of Events | Percent with Events |
Total | 108 | 48 | 44.44% |
Sex | |||
Male | 64 | 32 | 50.00% |
Female | 44 | 16 | 36.36% |
Gestational age (wks) | |||
32–37 | 35 | 8 | 22.86% |
28–31 | 55 | 26 | 47.27% |
<28 | 18 | 14 | 77.78% |
Body Weight (g) | |||
1500–2499 | 40 | 8 | 20.00% |
1000–1499 | 47 | 24 | 51.06% |
<1000 | 21 | 16 | 76.19% |
Apgar 1 min | |||
7–10 | 52 | 19 | 36.54% |
4–6 | 34 | 15 | 44.12% |
0–3 | 22 | 14 | 63.64% |
Apgar 5 min | |||
7–10 | 62 | 24 | 38.71% |
4–6 | 45 | 23 | 51.11% |
0–3 | 1 | 1 | 100.00% |
Normal LDH at 1 day of life (135–750 U/L) | |||
Yes | 60 | 28 | 46.67% |
No | 48 | 20 | 41.67% |
Normal aPTT at 1 day of life (23–35 s) | |||
Yes | 13 | 8 | 61.54% |
No | 95 | 40 | 42.11% |
Normal Prothrombin Time 1 day of life (11–14 s) | |||
Yes | 42 | 17 | 40.48% |
No | 66 | 31 | 46.97% |
Iron administered within 7–21 days of life | |||
Yes | 60 | 36 | 60.00% |
No | 48 | 12 | 25.00% |
AOP at 1 day of life | |||
Yes | 7 | 5 | 71.43% |
No | 101 | 43 | 42.57% |
EPO administered in first 7 days | |||
Yes | 49 | 12 | 24.49% |
No | 59 | 36 | 61.02% |
Characteristics | EPO administered within 7 days of life (n = 49) | EPO not administered within 7 days of life (n = 59) | P value |
---|---|---|---|
Male | 26 (53.06%) | 38 (64.41%) | 0.169 |
Female | 23 (46.94%) | 21 (35.59%) | 0.880 |
GA, weeks | 29.71 ± 2.88 | 30.12 ± 2.31 | 0.420 |
BW, g | 1365.41 ± 470.54 | 1405.15 ± 397.38 | 0.635 |
Apgar score at 1 min | 5.80 ± 2.04 | 5.53 ± 2.51 | 0.538 |
Apgar score at 5 min | 6.53 ± 1.66 | 6.58 ± 1.38 | 0.876 |
Hb at 1 day of life, g/dL | 15.52 ± 3.23 | 15.22 ± 2.51 | 0.585 |
HCT at 1 day of life, % | 46.01 ± 6.96 | 43.72 ± 6.77 | 0.086 |
RBC count at 1 day of life, million/μL | 4.28 ± 0.63 | 4.13 ± 0.63 | 0.214 |
aPTT at 1 day of life, s | 56.06 ± 37.75 | 52.83 ± 19.60 | 0.569 |
PT at 1 day of life, s | 15.78 ± 5.43 | 16.36 ± 4.42 | 0.541 |
LDH at 1 day of life, U/L | 726.67 ± 368.84 | 804.62 ± 396.23 | 0.296 |
Serum EPO at 1 day of life, mIU/mL | 2.25 ± 1.06 | 9.41 ± 5.00 | <0.001 |
AOP at 1 day of life | 4 (8.16%) | 3 (5.08%) | 1.000 |
Characteristics | Without AOP at 21 days of life (n = 30) | With AOP at 21 days of life (n = 78) | P value |
---|---|---|---|
Male | 14 (46.67%) | 50 (64.10%) | <0.001 |
Female | 16 (53.33%) | 28 (35.90%) | 0.097 |
GA, weeks | 30.90 ± 2.26 | 29.56 ± 2.61 | <0.05 |
BW, g | 1526.83 ± 434.50 | 1333.38 ± 419.38 | <0.05 |
Apgar score at 1 min | 6.27 ± 1.95 | 5.41 ± 2.39 | 0.083 |
Apgar score at 5 min | 6.97 ± 1.56 | 6.40 ± 1.46 | 0.078 |
Hb at 1 day of life, g/dL | 16.46 ± 3.01 | 14.94 ± 2.68 | <0.05 |
HCT at 1 day of life, % | 47.00 ± 8.56 | 43.90 ± 6.02 | <0.05 |
RBC count at 1 day of life, million/μL | 4.48 ± 0.76 | 4.09 ± 0.54 | <0.01 |
aPTT at 1 day of life, s | 58.76 ± 47.02 | 52.58 ± 18.39 | 0.326 |
PT at 1 day of life, s | 15.01 ± 4.45 | 16.52 ± 5.01 | 0.151 |
LDH at 1 day of life, U/L | 808.17 ± 445.65 | 754.29 ± 359.95 | 0.517 |
Serum EPO at 1 day of life, mIU/mL | 4.77 ± 4.05 | 6.70 ± 5.49 | 0.083 |
Iron administered during 7th–21st day of life | 12 (40.00%) | 48 (61.54%) | <0.001 |
EPO administered in first 7 days of life | 3 (10.00%) | 4 (5.13%) | 0.058 |
Characteristics | Transfusions not required in first 21 days of life (n = 60) | Transfusions required in first 21 days of life (n = 48) | P value |
---|---|---|---|
Male | 32 (53.30%) | 32 (66.67%) | 1.000 |
Female | 28 (46.67%) | 16 (33.30%) | 0.970 |
GA, weeks | 30.87 ± 2.31 | 28.77 ± 2.44 | <0.001 |
BW, g | 1539.75 ± 423.64 | 1196.33 ± 360.12 | <0.001 |
Apgar score at 1 min | 6.08 ± 2.00 | 5.10 ± 2.55 | <0.05 |
Apgar score at 5 min | 6.80 ± 1.49 | 6.25 ± 1.48 | 0.059 |
Hb at 1 day of life, g/dL | 16.16 ± 2.88 | 14.36 ± 2.49 | <0.01 |
HCT at 1 day of life, % | 47.15 ± 5.96 | 41.76 ± 6.92 | <0.001 |
RBC count at 1 day of life, million/μL | 4.42 ± 0.54 | 3.93 ± 0.64 | <0.001 |
aPTT at 1 day of life, s | 53.72 ± 34.14 | 55.02 ± 21.71 | 0.819 |
PT at 1 day of life, s | 15.77 ± 4.75 | 16.51 ± 5.07 | 0.432 |
LDH at 1 day of life, U/L | 783.17 ± 371.03 | 751.88 ± 403.45 | 0.676 |
Serum EPO at 1 day of life, mIU/mL | 4.28 ± 2.91 | 8.51 ± 6.35 | <0.001 |
EPO administered in first 7 days of life | 37 (61.67%) | 12 (25.00%) | <0.01 |
Characteristics | OR (95% CI) | P value | AOP Incidence rate* |
---|---|---|---|
Sex, male/female | 0.490 (0.209–1.150) | 0.101 | 78.13%/63.64% |
GA | 0.802 (0.668–0.963) | <0.05 | |
BW | 0.999 (0.999–1.000) | <0.05 | |
Apgar score at 1 min | 0.836 (0.680–1.026) | 0.087 | |
Apgar score at 5 min | 0.765 (0.566–1.034) | 0.081 | |
Hb at 1 day of life | 0.776 (0.635–0.949) | <0.05 | |
HCT at 1 day of life | 0.930 (0.868–0.997) | <0.05 | |
RBC count at 1 day of life | 0.316 (0.139–0.716) | <0.01 | |
aPTT at 1 day of life | 0.993 (0.980–1.007) | 0.356 | |
PT at 1 day of life | 1.083 (0.970–1.208) | 0.155 | |
LDH at 1 day of life | 1.000 (0.999–1.001) | 0.514 | |
Serum EPO at 1 day of life | 1.093 (0.986–1.212) | 0.090 | |
Iron administered during 7th–21st day of life, yes/no | 2.400 (1.014–5.678) | <0.05 | 80.00%/62.50% |
EPO administered in first 7 days of life, yes/no | 0.440 (0.186–1.039) | 0.061 | 63.27%/79.66% |
Characteristics | OR (95% CI) | P value | Transfusion Incidence rate* |
---|---|---|---|
Sex, male/female | 1.750 (0.798–3.840) | 0.163 | 50.00%/36.36% |
GA | 0.694 (0.578–0.833) | <0.001 | |
BW | 0.998 (0.997–0.999) | <0.001 | |
Apgar score at 1 min | 0.827 (0.696–0.982) | <0.05 | |
Apgar score at 5 min | 0.779 (0.599–1.012) | 0.062 | |
Hb at 1 day of life | 0.762 (0.640–0.907) | <0.01 | |
HCT at 1 day of life | 0.873 (0.812–0.938) | <0.001 | |
RBC count at 1 day of life | 0.230 (0.105–0.502) | <0.001 | |
aPTT at 1 day of life | 1.002 (0.989–1.015) | 0.818 | |
PT at 1 day of life | 1.032 (0.954–1.117) | 0.432 | |
LDH at 1 day of life | 1.000 (0.999–1.001) | 0.673 | |
Serum EPO at 1 day of life | 1.230 (1.103–1.372) | <0.001 | |
EPO administered in first 7 days of life, yes/no | 0.207 (0.090–0.478) | <0.001 | 24.49%/61.02% |
Characteristics | AOR (95% CI) | P value |
---|---|---|
GA | 0.952 (0.706–1.283) | 0.745 |
BW | 0.999 (0.998–1.001) | 0.401 |
Hb at 1 day of life | 0.669 (0.295–1.515) | 0.335 |
HCT at 1 day of life | 1.170 (0.864–1.585) | 0.310 |
RBC count at 1 day of life | 0.351 (0.073–1.698) | 0.193 |
Iron administration during 7th–21st day of life | 2.749 (1.064–7.106) | <0.05 |
Characteristics | OR (95% CI) | P value |
---|---|---|
Mild AOP | ||
GA | 1.087 (0.719–1.644) | 0.691 |
BW | 1.000 (0.998–1.002) | 0.908 |
Hb at 1 day of life | 0.640 (0.270–1.519) | 0.312 |
HCT at 1 day of life | 1.194 (0.854–1.671) | 0.300 |
RBC count at 1 day of life | 0.271 (0.031–2.345) | 0.236 |
Iron administered during 7th–21st day of life | 1.348 (0.373–4.880) | 0.649 |
Moderate AOP | ||
GA | 0.912 (0.667–1.247) | 0.564 |
BW | 0.999 (0.997–1.001) | 0.285 |
Hb at 1 day of life | 0.704 (0.307–1.614) | 0.407 |
HCT at 1 day of life | 1.154 (0.847–1.571) | 0.364 |
RBC count at 1 day of life | 0.366 (0.071–1.879) | 0.228 |
Iron administered during 7th–21st day of life | 3.564 (1.279–9.927) | 0.015 |
Severe AOP* |
Characteristics | AOR (95% CI) | P value |
---|---|---|
GA | 0.864 (0.619–1.204) | 0.387 |
BW | 0.998 (0.996–1.000) | 0.050 |
Apgar score at 1 min | 0.913 (0.714–1.167) | 0.467 |
Hb at 1 day of life | 0.850 (0.581–1.243) | 0.401 |
HCT at 1 day of life | 0.944 (0.785–1.136) | 0.544 |
RBC count at 1 day of life | 0.695 (0.134–3.611) | 0.665 |
Serum EPO at 1 day of life | 1161 (0.964–1.398) | 0.117 |
EPO administered in first 7 days of life, yes/no | 0.236 (0.042–1.333) | 0.102 |
Hb level at 21 days of life | HCT level at 21 days of life | Serum EPO at 21 days of life | ||
EPO administration in first 7 days of life | Percentage of variance explained | 10** | 6.7** | 20.1** |
p-value | <0.01 | <0.05 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated